NAD+ injectable NAD+

An injectable form of a molecule cells need for energy production, popular at IV-therapy clinics for anti-aging and energy claims. Most solid human research has actually studied pill forms of related compounds, not injections, so injectable NAD+ specifically lacks its own dedicated safety and effectiveness data.

Also known as Nicotinamide adenine dinucleotide, nadide, coenzyme I, beta-NAD, Codehydrogenase I, Codehydrase I, diphosphopyridine nucleotide, Cozymase I

Effects Focus Longevity

Routes Injectable Subcutaneous

Legal status Dietary supplement

WADA Not listed

3D Molecular Structure of C₂₁H₂₇N₇O₁₄P₂

Drag to rotate · scroll to zoom

Chemistry

Formula: C21H27N7O14P2
Molar mass: 663.4
CAS: 53-84-9
PubChem CID: 5892
IUPAC name: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
InChIKey: BAWFJGJZGIEFAR-NNYOXOHSSA-N

Reported dosing

Limited data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100-500 mg per injection

Reported range 50-1000 mg per session, often administered as slow IV push or IM injection at wellness clinics

Route Intravenous or intramuscular injection

Frequency 1-3 times weekly, or periodic clinic sessions

Duration Ongoing (as offered by wellness/longevity clinics)

Compounded and sold at wellness clinics without FDA approval as a standardized drug product; rapid IV administration has been associated with chest tightness and flushing in reported cases, and rigorous controlled human efficacy data is limited.

Where this comes from Clinic/compounding-pharmacy marketing literature; limited independent clinical evidence

Human data for this compound is limited. Read the figures above as a record of reported use rather than established dosing.